460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers

Komal Jhaveri, Hyo S. Han, Efrat Dotan, D-Y. Oh, C. Ferrario, Anthony W. Tolcher, Kyung-Woo Lee, C-Y. Liao, Y-K. Kang, Yeul Hong Kim, E.P. Hamilton, A. Spira, Naresh Patel, Christos S. Karapetis, Sun Young Rha, Lisa Boyken, Joseph Woolery, Phillipe Bedard